Theravance Biopharma Raised to $17 Despite Doubts

B. Riley raised its price target on Theravance Biopharma to $17 from $14, while maintaining a Neutral rating. The broker pointed to the final settlement of the dispute with MannKind, which secures exclusivity for certain products and provides greater visibility into part of future revenue. Despite this positive signal, the backdrop remains fragile for TBPH. The stock has fallen sharply in recent months after the failure of a flagship drug in late-stage trials, forcing the company to rethink its strategy and restructure its pipeline. The shares could therefore remain volatile, caught between occasional analyst support and lingering uncertainty over growth.